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Background: The objective of this work was to assess the overall survival, cause-specific survival and biochemical
failure-free survival of a contemporary cohort of patients with localized prostate cancer (PCa) treated with
intensity-modulated radiation therapy (IMRT) or radical prostatectomy (RP).
Methods: We did a retrospective cohort study of our institution’s registry of patients undergoing either IMRT or RP
between January 1999 and March 2010, and assessed Prostate Specific Antigen (PSA), age at diagnosis, Gleason score,
and digital rectal examination. Two groups were separated according to RP or IMRT treatment and these groups were
in turn divided into risk groups according to the D’Amico classification. Overall survival (OS), cause-specific survival
(CSS), mortality from other causes (MOC), and biochemical disease-free survival (BDFS) were assessed.
Results: Twelve-hundred patients were included: 993 in the RP group and 207 in the IMRT group.
The IMRT group had older age, PSA at diagnosis and a significantly higher percentage of cancer on the needle biopsy
(p <0.001). Of the 207 patients who underwent IMRT, 54% presented comorbidities. Median follow-up was 91.7 months
for the RP group and 76 months for the IMRT group. The OS at 5 and 7 was 96.2, and 93.7 for the RP group respect-
ively and 88.4, and 83.1 for the IMRT group respectively (p <0.001). There were no significant differences in the CSS in
relation to treatment received among the low- and high-risk groups, while in the intermediate-risk group, patients
who underwent to RP had a higher CSS than patients who underwent IMRT (99.6% vs 94.1%, p = 0.003). The IMRT
group had a significantly better BDFS than the RP group (86.4% vs. 74.3%, respectively, p = 0.016).
Conclusions: Patients treated with RP were significantly younger and had a better prognosis than patients treated
using IMRT, and according to our results, RP had better outcomes in terms of OS while IMRT had greater MOC.
Treatment modality did not affect the CSS.
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Prostate cancer (PCa) is the most common cancer in
men. The annual incidence of PCa in the USA is esti-
mated to be 241.740, representing 29% of all cancers
[1]. In Chile, PCa is the second leading cause of cancer
death in men, with a mortality rate of 20.2/100.000,
surpassing lung cancer and only being surpassed by
gastric cancer. It is the eighth leading cause of overall
death in men [2-4].* Correspondence: tomasmerinolara@gmail.com
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reproduction in any medium, provided the orCurrently, the treatments of choice for low-,
intermediate- and high-risk localized PCa are radical pros-
tatectomy (RP) and radiotherapy (RT), which have been
considered as curative treatments with comparable onco-
logic outcomes [5-7]. Because of this, there has been no
final consensus as to which treatment is the best choice
for a patient with localized PCa. Both RP and RT decrease
cause-specific mortality from PCa compared with watch-
ful waiting, as shown in a recent systematic review by
Chou et al. [8]. Other systematic reviews [9] show better
results in recurrence-free survival at 5 years for RP
compared with external RT (14% vs. 39%, respectively,
p = 0.04); however, both reviews conclude that theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions in the evidence.
As for RP, surgical techniques have been added, such
as the preservation of the neurovascular bundles and la-
paroscopy or robotic surgery to improve outcomes and de-
crease complications. Radiotherapy has advanced towards
intensity-modulated radiation therapy (IMRT). IMRT is a
new technique that modulates the radiation beam so that it
achieves a more conformal dose distribution to the target
and spare more normal tissues Thus, in PCa, IMRT allows
an increase of the prostate radiation dose and reduces tox-
icity in the rectum and bladder. Sheets et al. [10] showed
that increasing the radiation dose improves recurrence-free
survival and furthermore concluded that IMRT had fewer
gastrointestinal side effects and lower rates of hip fracture
than conventional RT. There are several inconclusive sys-
tematic reviews comparing radiation treatments [11,12].
However, according to a recent review by Bauman et al.
[13], which included 11 studies with over 4500 patients,
IMRT would have an advantage over three-dimensional
conformal RT (3DCRT) in localized PCa requiring more
than 70 Gy, and therefore should become the treatment of
choice for these patients. Thus, 3DCRT has largely been
supplanted by IMRT as the external beam radiation tech-
nique of choice. In 2000, 0.15% of treatments were carried
out using IMRT compared with 95.9% in 2008 [10].
To our knowledge, there is only one study comparing
IMRT and RP [14], since most studies compare RT (without
specifying the RT technique) with surgery. Therefore, our
objective was to assess outcomes such as overall survival (OS),
cause-specific survival (CSS), mortality from other causes
(MOC) and biochemical disease-free survival (BDFS) in a con-
temporary cohort of over one thousand patients with localized
PCa treated with IMRT or RP in a Chilean population.
Methods
Patients
We did a retrospective cohort study of the Urology and
Radiotherapy Department records of the Pontificia Uni-
versidad Católica de Chile for patients with a clinically
localized PCa diagnosis who were treated with definitive
RP or IMRT (without hormone therapy) between January
1999 and March 2010.
In compliance with the Helsinki Declaration, ethical
approval, as well as permission to access the database
used in this study, was provided by the local research
ethics committee of the Pontificia Universidad Católica
de Chile. Due to the retrospective, non interventional
nature of this study, no consent was requested by the
local research ethics committee.
Staging and risk groups
Characteristics were assessed prior to treatment, and in-
cluded age at diagnosis, PSA at diagnosis, Gleason score,percentage of cancer on the needle biopsy (calculated as
the sum of the length of PCa in positive cores, divided
by the total sum of all core lengths) and digital rectal
examination (DRE). A bone and CT scan of the abdo-
men and pelvis were requested in patients of intermedi-
ate and high risk, meeting the NCCN criteria [15].
Patients were stratified according to the D’Amico classi-
fication [16] and according to the Charlson comorbidity
index (CCI) [17] for the IMRT group (no information
was available for the RP group).
Treatments
Following an explanation of therapeutic alternatives,
treatment selection between RP or IMRT was decided
by the patient with the urologist. Poor surgery candi-
dates and those who preferred IMRT to PR were re-
ferred to radiotherapy.
Patients undergoing surgery underwent open or laparo-
scopic RP surgery, and lymphadenectomy was performed
on patients of high and intermediate risk. For the IMRT
technique, a bracing system was used with the patient in
the supine position immobilized with a VacLoc (Civco,
Iowa) device. Patients underwent CT simulation with a
full bladder and empty rectum using an axial slice separ-
ation of 3 mm. The treatment volume was defined to in-
clude the prostate (for low risk) and prostate plus seminal
vesicles (SSVV) for intermediate and high-risk patients,
with a safety margin to account for positioning errors and
prostate movements (Planning Target Volume (PTV) [18]
for 0.8 cm anterior, lateral and superior-inferior to the
prostate, and 0.6 cm towards the posterior. PTV for SSVV
was 1.2 cm anterior; the other dimensions had the same
margins as the prostate PTV). The bladder, femoral heads,
rectum, and midrectum (defined as the rectum at the
height of the PTV) were also drawn. The dose per fraction
was 2 Gy. Initially, 46 Gy were administered to the prostate
and seminal vesicles, followed by a 30 Gy boost to the pros-
tate only to complete 76 Gy in 39 fractions over 7 ½weeks.
A 95% coverage of the prescribed dose was required for
95% of the volume. The rectal dose constraints were 77 Gy
to <10%, 60 Gy to <30%, and 40 Gy to <60%; the midrec-
tum constraints were 39 Gy to <50%, bladder constraint
was 40 Gy to <60%, and the femoral head constraint was
36 Gy to <30%.
Follow-up
Follow-up time started from the day of surgery in the
RP group or from the start of radiotherapy for the IMRT
group. Patients were followed up with clinical controls
(PSA and DRE) every 3 months for the first 2 years, then
every 6 months until 5 years, and then annually.
Biochemical failure was defined as two consecutive
PSA findings of 0.2 ng/mL for the RP group and accor-
ding to the Phoenix consensus (a rise in PSA is greater
Table 1 Patient characteristics of the RP and IMRT groups
RP IMRT p
No. of patients 993 207
Mean age (95% CI) 63 (62.6–63.5) 70 (69–71) p < 0.001*
Mean PSA (95% CI) 9.8 (9.1–10.5) 13.6 (11.8–16.6) p < 0.001*
Mean % PCa biopsy
(95% CI)
17.6 (16.1–18.9) 25.7 (22–29.6) p < 0.001*
DRE p < 0.001†
T1 (n/%) 537/ 53.7% 84/ 40.6%
T2 (n/%) 175/ 18% 70/ 34%
T3 (n/%) 29/ 4% 53/ 26%
T4 (n/%) 0 0
Unknown (n/%) 266/26.7% 0
D’Amico classification p < 0.001†
Low risk (n/%) 194/19.5% 40/19.3%
Intermediate risk (n/%) 525/52.9% 79/37.7
High risk (n/%) 216/21.7% 78/38%
Unknown (n/%) 56/5.6% 10/4.89
*p values from unpareid t test for two means. †p values from chi-square test.
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by the PSA) for IMRT [19].
Statistical analysis
Death from prostate cancer was considered for all the
death certificates that mentioned prostate cancer within
the causes of death.Figure 1 Overall survival according to treatment. IMRT: Intensity-ModuThe OS, CSS, MOC and BDFS were analyzed globally
and according to D’Amico risk for each group. The
Kaplan-Meier method was used and log rank to compare
curves. We used a Cox proportional hazard regression
model for multivariate analysis. Analysis was performed
using IBM SPSS v19.
Results
Patient characteristics
A total of 1200 patients were included: 993 in the RP
group and 207 in the IMRT group. Patient characteris-
tics are given in Table 1. It was observed that the RP
group was significantly younger (p = 0.001) than the
IMRT group, with average ages of 63 and 70 years, re-
spectively (CI, 62.6–63.5 and 69–71 years, respectively).
Furthermore, patients undergoing IMRT had a signifi-
cantly higher PSA than those of the RP group, with an
average of 9.8 ng/mL for the RP group and 13.6 ng/mL
for the IMRT group (p <0.001). The amount of cancer
on the needle biopsy was higher in the IMRT group
(25.7%) than in the RP group (17.6%) (p <0.001).
When dividing by risk groups according to D’Amico
classification, it was observed that about 70% of patients
undergoing RP had low or intermediate risk, while the
best percentage of patients undergoing IMRT were of
intermediate or high risk, making it a significant diffe-
rence (p <0.001).
No patients in the RP group received neo-adjuvant An-
drogen Deprivation therapy (ADT). On the other hand,lated Radiation Therapy. RP: Radical Prostatectomy. OS: Overall Survival.
Table 2 Overall survival according to treatment and risk groups to 5 and 7 years
Overall survival 5 years (%) 95% CI 7 years (%) 95% CI p value
All patients RP 96,2 0.948-0.972 93,7 0.917-0.952 <0.001
IMRT 88,4 0.827-0.923 83,1 0.760-0.883
Low risk RP 96,5 0.924-0,984 95,7 0.912-0.979 0.97
IMRT 97,4 0.825-0.996 97,4 0.825-0.996
Intermediate risk RP 97,3 0.955-0.984 95,5 0.931-0.971 <0.001
IMRT 86,3 0,761-0.924 80,4 0.683-0.883
High risk RP 92,7 0.879-0.956 87,5 0.816-0.916 0.02
IMRT 85,1 0.729-0.921 77,3 0.625-0.868
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12%, 34% and 76% for the low, intermediate and high
risk group. Of the 87 patients who received ADT, 8 re-
ceived only peripheral anti-androgen therapy and 79 re-
ceived central ADT with GnRH analogues. In the high
risk 24% was treated with prolonged ADT (≥ 2 years),
39% was treated with short ADT (≤6 years), in 37% the
duration of ADT is unknown.Figure 2 Mortality from other causes according to treatment. IMRT: In
Mortality for other causes.During the study period no adjuvant RT or ADT was
indicated after RP. Patients were followed with PSA and if
biochemical failure was diagnosed, early RT salvage was
indicated. Of 993 patients of the RP group, 253 patients
(25%) had biochemical failure, of whom 48 patients re-
ceived salvage RT with curative intent in our center.
Of the 207 patients who uderwent IMRT, 54% pre-
sented comorbidities, the most common being Diabetestensity-Modulated Radiation Therapy. RP: Radical Prostatectomy. MOC:
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structive Pulmonary Disease. Over 45% of patients
undergoing IMRT had CCI ≥ 1 and 92% had CCI age-
adjusted ≥ 1. CCI could not be calculated in the RP group
because the information needed was not available.
Treatment outcomes
Median follow-up was 91.7 months for the RP group
and 76 months for the IMRT group. OS at 5 and
7 years was 96.2% and 93,7% for the RP group and
88,4% and 83,1% for IMRT group (p <0.001) (Figure 1).
Intermediate- and high-risk patients who underwent RP
had a longer survival than those who underwent IMRT at 5
and 7 years (p <0.001 to intermediate risk and p = 0.02 to
high risk, Table 2).
Figure 2 shows MOC for the RP group and IMRT
group, which shows that the MOC is higher for the
IMRT group at 5 and 7 years (p <0.001). Figure 3 shows
MOC for the IMRT group according CCI adjusted for
age (categorized into <3 or ≥ 3 points). As expected, pa-
tients with greater CCI have higher mortality from other
causes (p = 0.046).Figure 3 Mortality from other causes in IMRT group according CCI ad
Mortality for other causes. CCI: Charlson Comorbidity Index.Analysis of CSS are shown in Table 3 and Figure 4.
We found that CSS is higher in the RP group than
IMRT group (98.1 vs 92.1, p < 0.001) and highlighting
that there was no significant difference in CSS in the
low- and high-risk groups, while in the intermediate-risk
group, patients who underwent RP had a statistical sig-
nificant, although minimal longer cancer-free survival
than patients who underwent IMRT at 7 years (99.8% vs
98.6% p = 0.003).
BDFS was 75% for the RP group and 88% for the
IMRT group at 36 months (p = 0.016). The BDFS at
36 months for RP group was 87%, 80% and 56%, for
the low-, intermediate- and high-risk groups, respect-
ively .for to the IMRT group, BDFS was 95%, 92% and
79% for the low-, intermediate- and high-risk (Figure 5).
Only in the high-risk group there was significant diffe-
rence in BDFS (p = 0.03).
Multivariate analysis for Cause-Specific Mortality (CSM)
(Table 4) showed that Gleason score ≥8, DRE ≥T2b and
DRE ≥T3 predicted CSM (HR 7.18, HR 5.67 and HR 8.38,
respectively). The treatment does not affect the CSM (HR
1.706, 95% CI 0.730–3.987, p = 0.218)justed for age. IMRT: Intensity-Modulated Radiation Therapy. MOC:
Table 3 Cancer-Specific Survival according to treatment
and risk groups to 7 years
Cancer-specific survival 7 years (%) 95% CI p value
All patients RP 98.1 0.968-0.989 <0.001
IMRT 92.1 0.858-0.957
Low risk RP 99.3 0.951-0.999 0.089
IMRT 97.4 0.825-0.996
Intermediate risk RP 99.6 0.983-0.999 0.003
IMRT 94.1 0.823-0.981
High risk RP 93.0 0.878-0.960 0.07
IMRT 85.4 0.704-0.932
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To our knowledge, this is the first study in Chile and the
second in the wider literature comparing IMRT results
with RP in a contemporary cohort of patients. The main
strength of our study lies in the number of patients and
the follow-up of patients, with a median follow-up time
of 91 months for the RP group and 76 months for the
IMRT group, which provides not only results as BDFS,
but also clinical outcomes such as OS and, more import-
ant, Cancer-Specific Survival.
The prevalence of surgical treatment over IMRT is
highlighted in the studied period where 82.7% of patients
received RP versus only 17.3% who were treated with
IMRT. This treatment pattern significantly differs from
the literature, as for example, the Abdollah study [20],
which describes a study of 68,665 patients in the SEER
database, of which 67% received radiotherapy. Other
studies, such as Schymura et al. [21], with 3500 patients,
showed that 31% received RT, 39% RP and 28% did not
receive locoregional treatment. Our center began using
IMRT routinely in 2001, when only 0.9% of RT treat-
ments in the U.S.A were using this technique [22].Figure 4 Cancer-Specific Survival to 7 years according to risk groups.
RP: Radical Prostatectomy. CSS: Cause-Specific Survival.The RP and IMRT groups differed in the baseline
characteristics, both in age and other variables (PSA,%
of PCa in the biopsy, DRE). Patients who underwent
IMRT were older and had a higher risk PCa, which is re-
peated in different series. For example, in 2009, Aizer
et al. [14] compared IMRT with RP and observed that
the patients who underwent RT were significantly older
and had a higher Gleason score (p <0.001).
Another aspect highlighted in the literature is that patients
undergoing RT have higher comorbidity (Charlson comor-
bidity index) than RP patients. [20]. In the current study, we
observed that in the IMRT group, patients with higher age-
adjusted CCI had increased mortality from other causes
(p = 0.039). The comorbidity of our surgical patients was not
systematically studied during this period, although it is likely
that those patients with more comorbidities were referred to
radiotherapy as described in a previous study [23]. RT treat-
ment was preferred for older patients and those with higher
surgical risk because as mentioned, there is no single decisive
criterion between RT or RP; and therefore it depends on pa-
tient features and preference.
Our results showed a better OS at 5 and 7 years for
the RP group than the IMRT group. However, mortality
from other causes is higher in the IMRT group and no
difference in cancer-specific mortality between the two
groups was found. This could be explained by older age
and the high comorbidities in the IMRT group.
The best results in terms of OS, despite the higher rate
of biochemical failure in the RP group, raise the possibil-
ity that a significant percentage of these patients with
biochemical recurrence may have received some form of
salvage therapy (possibly with RT) while primarily irradi-
ated patients would not have the opportunity to receive
a curative salvage treatment like RP in our facilities.
Univariate analysis showed that RP group has a
higher CSS than IMRT group. However, when analyzingCI: Confidence Interval. IMRT: Intensity-Modulated Radiation Therapy.
Figure 5 Biochemical Disease-Free Survival at 36 months according to risk groups. CI: Confidence Interval. IMRT: Intensity-Modulated
Radiation Therapy. RP: Radical Prostatectomy. BDFS: Biochemical Disease-Free Survival.
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intermediate-risk group in favor of the RP treatment.
Also, the multivariate analysis showed no significant dif-
ferences between RP and IMRT for CSS.
Regarding BDFS, there were significant global and spe-
cific differences between IMRT and RP in the high-risk
group. This result is similar to the one presented by
Aizer et al. [14]: regarding IMRT or RP treatment, low-
and intermediate-risk groups showed no difference in bio-
chemical failure; however, the high-risk group showed a
difference in favor of IMRT over RP (62.2% vs. 38.4% re-
spectively, p <0.001), which the authors attributed to the
use of hormone therapy in the IMRT group. In our re-
sults, it is striking that despite having better BDFS, the
IMRT group had worse OS. This could be explained be-
cause IMRT patients are typically older and probably have
greater comorbidity, as previously discussed, so their OS
decreases because of other causes of death (Figure 2).Table 4 Multivariate analysis of cancer-specific mortality
Variable HR 95% CI p
Age 0.987* 0.942-1.033 0.567
RP Reference
IMRT 1.706 0.730-3.987 0.218
DRE T1-T2a Reference
DRE T2b-T2c 5.674 2.205-14.599 0.001
DRE ≥ T3 8.380 3.179-22.091 0.001
Gleason score ≤6 Reference
Gleason score =7 1.397 0.512-3.810 0.514
Gleason score ≥8 7.183 2.777-18.574 0.001
PSA ≤ 10 ng/mL Reference
PSA > 10 and ≤20 ng/mL 0.333 0.111-0.994 0.049
PSA > 20 ng/mL 0.984 0.427-2.268 0.971
*HR for age expressed per year increase.Currently, IMRT is a therapy recommended by the
NCCN [20] that has shown good results in Chile [23],
and we know that there has been progress in its appli-
cation, especially when combined with hormone ther-
apy. The aforementioned study by Aizer et al. [14]
concluded that high risk patients who underwent
IMRT plus hormone therapy had better BDFS. Mean-
while, a study by Parikh et al. [24] showed a similar re-
sult: external RT (method was not specified) combined
with ADT was better than surgery plus adjuvant RT
for high-risk PCa. We can then assume that the IMRT
outcomes in our study could be improved by long term
ADT in high risk patients, a protocol that is already
being used in our Cancer Center. Currently, there is
abundant evidence confirming that patients with high-
risk PCa would benefit from prolonged ADT, improv-
ing their OS and CSS [25-27]. Another aspect that
could benefit the IMRT outcomes is to treat the pelvic
nodes that could de potentiality involved in high-risk
patients. Prophylactic pelvic RT is recommended by
some groups [28] despite not having adequate rando-
mized studies that support it.
A major limitation of our current study is that we do
not have the CCI for RP group, which could have
allowed us to better clarify the specific causes of mortal-
ity in patients who underwent RP. Another limitation is
that we have limited information regarding adjuvant
therapy (ADT or RT) received by RP group, since we
cannot rule out that they have been treated in other
centers. Different definitions of biochemical failure may
favor the IMRT because the definition of 0.2 ng/mL for
recurrence in the RP group is more sensitive to the def-
inition of Phoenix consensus [19] used for the IMRT
group. However these definitions are commonly used in
the clinic and are crucial to define further treatment
promptly; therefore we decided to use them despite
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study is also a weakness because it does not rule out
confounding variables that could alter the results. The
high percentage of surgery patients suggests a selection
bias against IMRT patients and although this bias could
be minimized by multivariate analysis it cannot be ruled
out.
This study confirms the results of other retrospective
studies and emphasizes the importance of randomized
trials that minimize selection bias of patients.
We look forward to the results of the study Protect T
trial (NCT00632983). This study aims to compare the re-
sults of RP, conformal radiotherapy and active surveillance,
outcomes include disease-specific survival at 10 years,
treatment complications and quality of life. These results
are expected in 2016 and have the potential to change the
way we face this disease.
Conclusions
In conclusion, we found that patients treated with RP
were significantly younger and had a better prognosis
than patients treated with IMRT. RP had better out-
comes in terms of OS, however IMRT has greater
MOC. There is a need for further prospective studies of
both treatments modalities, with a larger number of pa-
tients and longer follow-up.
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